Regulation & Approvals
Dicot Pharma Gets EU Approval to Run LIB-01 Phase 2b Study in Sweden
By News Desk ·
Key takeaways
- Sweden became the first EU country to approve Dicot Pharma's LIB-01 phase 2b study.
- EU dosing for part II can begin only after the US part I is completed, expected in Q1 2027.
- The study plans at least 200 participants and will inform dose selection for phase 3.
Dicot Pharma AB received approval to conduct its LIB-01 phase 2b study in Sweden, the first EU country to grant approval, TradingView reported on November 19, 2026. Dosing in the EU for part II can begin after part I is completed in the US, expected in Q1 2027.
What Sweden's Approval Covers
Dicot Pharma is a Swedish clinical-stage pharmaceutical company developing LIB-01, an oral drug candidate targeting erectile dysfunction and premature ejaculation. The Swedish approval advances the planned EU trial and enables preparations for the efficacy portion, subject to completion of US part I.
The study plans at least 200 participants and is designed to generate efficacy data and inform dose selection for phase 3. Planned doses are 25 mg, 50 mg and a third dose to be determined; that third dose depends on part I, leaving the final dose range undecided.
The US part I is the dose-determination stage and is expected to finish in Q1 2027. EU part II dosing is contingent on completing it, and the timing remains an expectation.
Dicot Pharma's Funding and Trial Setup
According to akta.pro company records, Dicot Pharma completed a rights issue and directed share issue in May 2026 raising approximately SEK 231 million (~$22 million), oversubscribed to 134%, to finance the phase 2b study of LIB-01 in the USA and Europe. The same records show the company signed an agreement in December 2025 with a global CRO to conduct the phase 2b study, planned to start in late 2026 across the USA and Europe.
Earlier Steps Toward the Phase 2b Study
In June 2026, Dicot Pharma received FDA clearance to start the first part of its phase 2b study, which will determine the highest dose for the efficacy portion, MarketScreener reported. The company must obtain additional toxicology data to launch the second part in the US, moving up a planned preclinical study.
Dicot Pharma's share issue was oversubscribed at approximately 126% of the guarantee level in June 2026, providing about SEK 210 million before issue costs, Biostock reported. The company planned a directed issue of up to SEK 21 million to fund development of LIB-01.
In August 2026, three abstracts regarding LIB-01 were selected for oral presentation at the Sexual Medicine Society of North America's congress in Orlando, MarketScreener reported.
LIB-01's Next Milestone
Completion of US part I, expected in Q1 2027, is the step that precedes EU part II dosing, after which the study is designed to inform dose selection for phase 3.